Study S001337

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01973231
Acronym: LIRA-LIXI™
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 404
Start: 2013-10
Primary completion: 2014-11
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:lixisenatide
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2012-004984-27; OTHER:U1111-1136-3644

Registered primary outcomes

Change in Glycosylated Haemoglobin (HbA1c) From Baseline [Week 0, week 26]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0015602	Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain. Mezquita-Raya P, Diabetes therapy : research, treatment and education of diabetes and related disorders	2017	Nonrandomized study	PMID 28224463 DOI	cites ClinicalTrials.gov:NCT01973231
R0016660	Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide. Hunt B, Clinical therapeutics	2017	Nonrandomized study	PMID 28625506 DOI	cites ClinicalTrials.gov:NCT01973231
R0017050	Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting. Hunt B, Diabetes, obesity & metabolism	2017	Nonrandomized study	PMID 28124820 DOI	cites ClinicalTrials.gov:NCT01973231; registry reference DERIVED:28124820
R0020866	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Nauck M, Diabetes care	2016	Randomized trial	PMID 27311491 DOI	cites ClinicalTrials.gov:NCT01973231; registry reference RESULT:27311491